In Brief: Biosite Diagnostics/Scios
This article was originally published in The Gray Sheet
Executive Summary
Biosite Diagnostics/Scios: Diagnostic test manufacturer Biosite gains license to utilize biopharmaceutical developer Scios' B-type natriuretic peptide detection technology in its point-of-care congestive heart failure diagnostic. The agreement calls for Biosite to pay licensing fees and product royalties to Scios, terms of which were not disclosed. San Diego-based Biosite also signed an identical deal with biopharmaceutical firm XOMA Corp., giving it access to XOMA's lipopolysaccharide binding protein technology for sepsis detection...
You may also be interested in...
Biosite/Xoma
Biopharmaceutical firm Xoma alleges San Diego-based Biosite Diagnostics breached its obligations under three license agreements relating to bacterial expression of antibodies. Biosite says it believes it is in "full compliance" with the agreements, signed in 1997, and that Xoma is seeking to renegotiate terms of the license agreements (1"The Gray Sheet" March 17, 1997, I&W-17)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.